Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehae758 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Towards a novel framework for identifying commonalities and differences in older people's end-of-life trajectories: aims and interdisciplinary mixed-methods approach of the ERC-funded TRAJECT project.
Palliat Care Soc Pract
December 2024
Vrije Universiteit Brussel (VUB) & Ghent University, End-of-Life Care Research Group, Brussels, Belgium.
Background: Older people who die from serious chronic disease typically experience long periods (months or years) of illness and complex fluctuations in their physical health and in their social, psychological and existential well-being. Our understanding of these end-of-life trajectories is very limited, focuses predominantly on physical function and clinical predictors and neglects inter-individual differences. A better understanding of end-of-life trajectories, including what is shared among people and what is individually specific, is needed for an optimal provision of palliative care and health services planning.
View Article and Find Full Text PDFEuropean Research Council-funded grant: unveiling the effect of chemicals on lipids.
Eur Heart J
December 2024
Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense, Denmark.
European Research Council-funded grant: development of a novel cardiac tissue model.
Eur Heart J
December 2024
Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Corso Duca Degli Abruzzi 24, 10129 Turin, Italy.
The lucent yet opaque challenge of regulating artificial intelligence in radiology.
NPJ Digit Med
March 2024
Data Science Office, Mass General Brigham, Boston, MA, USA.
Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study.
Br J Dermatol
July 2024
St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
Background: Biologic therapies have led to increasing numbers of patients with psoriasis who have clear or nearly clear skin. It is current practice to continue biologic therapy indefinitely in these patients, which contributes to a substantial long-term drug and healthcare burden. 'As needed' biologic therapy in psoriasis may address this; however, our understanding of patient and clinician perceptions of this strategy is limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!